Abstract
Tacrine was the first drug approved by FDA (US) for the treatment of Alzheimer's disease suffering patients. Nowadays, this agent has been withdrawn from the clinics due to secondary effects, which, most importantly, include hepatotoxicity. However, the research on new tacrine analogues devoid of these therapeutically undesirable effects, but benefiting of their high and well known positive cholinergic power, has produced a number of new non-hepatotoxic tacrines. In this context, our laboratory has recently prepared a new set of heterocyclic tacrines by changing the benzene ring present in tacrine by appropriate heterocyclic motifs. Based on this approach, in this review we summarize the results that we have found in the ChromenoPyranoTacrines, one of the families of tacrine analogues. This highlights their pharmacological profile, such as their cholinesterase inhibition power, calcium channel blockade, antioxidant capacity, Aβ-anti-aggregating, and neuroprotective properties. As a result of this work we have identified permeable, neuroprotective MTD tacrines racemic hit-tacrines 11-amino-12-(3,4,5-trimethoxyphenyl)-7,9,10,12-tetrahydro-8H-chromeno[2,3- b]quinolin-3-ol (6g) and 14-(3,4-dimethoxyphenyl)-9,11,12,14-tetrahydro-10H-benzo[5,6] chromeno [2,3-b] quinolin-13-amine (7i),devoid of toxic effects and showing potent anti-cholinesterasic properties, that deserve attention and further development in order to find new, and more efficient drugs, for AD therapy.
Keywords: Tacrine, ChromenoPyranoTacrines, Multi-Target-Directed (MTD) Ligands, Alzheimer's disease, Aβ-amyloid, Reactive oxygen species.
Current Topics in Medicinal Chemistry
Title:New Tacrines as Anti-Alzheimer's Disease Agents. The (Benzo)Chromeno- PyranoTacrines
Volume: 17 Issue: 31
Author(s): Maria Jesus Oset-Gasque*Jose Marco-Contelles*
Affiliation:
- Instituto de Investigacion en Neuroquimica. Universidad Complutense de Madrid. Ciudad Universitaria, 28040 Madrid,Spain
- Instituto de Investigacion en Neuroquimica. Universidad Complutense de Madrid. Ciudad Universitaria, 28040 Madrid,Spain
Keywords: Tacrine, ChromenoPyranoTacrines, Multi-Target-Directed (MTD) Ligands, Alzheimer's disease, Aβ-amyloid, Reactive oxygen species.
Abstract: Tacrine was the first drug approved by FDA (US) for the treatment of Alzheimer's disease suffering patients. Nowadays, this agent has been withdrawn from the clinics due to secondary effects, which, most importantly, include hepatotoxicity. However, the research on new tacrine analogues devoid of these therapeutically undesirable effects, but benefiting of their high and well known positive cholinergic power, has produced a number of new non-hepatotoxic tacrines. In this context, our laboratory has recently prepared a new set of heterocyclic tacrines by changing the benzene ring present in tacrine by appropriate heterocyclic motifs. Based on this approach, in this review we summarize the results that we have found in the ChromenoPyranoTacrines, one of the families of tacrine analogues. This highlights their pharmacological profile, such as their cholinesterase inhibition power, calcium channel blockade, antioxidant capacity, Aβ-anti-aggregating, and neuroprotective properties. As a result of this work we have identified permeable, neuroprotective MTD tacrines racemic hit-tacrines 11-amino-12-(3,4,5-trimethoxyphenyl)-7,9,10,12-tetrahydro-8H-chromeno[2,3- b]quinolin-3-ol (6g) and 14-(3,4-dimethoxyphenyl)-9,11,12,14-tetrahydro-10H-benzo[5,6] chromeno [2,3-b] quinolin-13-amine (7i),devoid of toxic effects and showing potent anti-cholinesterasic properties, that deserve attention and further development in order to find new, and more efficient drugs, for AD therapy.
Export Options
About this article
Cite this article as:
Oset-Gasque Jesus Maria*, Marco-Contelles Jose*, New Tacrines as Anti-Alzheimer's Disease Agents. The (Benzo)Chromeno- PyranoTacrines, Current Topics in Medicinal Chemistry 2017; 17 (31) . https://dx.doi.org/10.2174/1568026618666180112155928
DOI https://dx.doi.org/10.2174/1568026618666180112155928 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tianeptine: An Antidepressant with Memory-Protective Properties
Current Neuropharmacology Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models
Current Medicinal Chemistry Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Site Targeted Press Coated Delivery of Methylprednisolone Using Eudragit RS 100 and Chitosan for Treatment of Colitis
Recent Patents on Anti-Infective Drug Discovery Influence of the Novelty-Seeking Endophenotype on the Rewarding Effects of Psychostimulant Drugs in Animal Models
Current Neuropharmacology Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery Gabapentin for the Treatment of Cancer-Related Pain Syndromes
Reviews on Recent Clinical Trials Effects of Psychiatric Medications on Sleep and Sleep Disorders
CNS & Neurological Disorders - Drug Targets IFN-γ and TNF-α Gene Polymorphisms in Multiple Sclerosis Patients in Northwest Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Sepsis, Coagulation and Anticoagulants
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Inflammatory Biomarkers for Mood Disorders - A Brief Narrative Review
Current Pharmaceutical Design Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Meet Our Editor
Central Nervous System Agents in Medicinal Chemistry Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews K+ Channels of Müller Glial Cells in Retinal Disorders
CNS & Neurological Disorders - Drug Targets Gibberellins - A Multifaceted Hormone in Plant Growth Regulatory Network
Current Protein & Peptide Science Acute Human Toxicity of Macrocyclic Lactones
Current Pharmaceutical Biotechnology Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly <i>via</i> Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling
MicroRNA CRF Receptor Antagonists: Utility in Research and Clinical Practice
Current Medicinal Chemistry